Imbruvica (ibrutinib) — Highmark
any covered indication for a BTK inhibitor
Reauthorization criteria
- prescriber attests that the member is tolerating therapy
- member has experienced therapeutic response defined as disease improvement OR delayed disease progression
Approval duration
12 months